A Nomogram Model for Predicting Recurrence of Stage I–III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and Traditional Classical Predictors

References

• Raffone A, Travaglino A, Mascolo M, et al. TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol. 2019;155:374–383. doi:10.1016/j.ygyno.2019.08.019
   PubMed Web of Science ®Google Scholar
• Jiang P, Huang J, Deng Y, et al. Predicting recurrence in endometrial cancer based on a combination of classical parameters and immunohistochemical markers. Cancer Manag Res. 2020;12:7395–7403. doi:10.2147/CMAR.S263747
   PubMed Web of Science ®Google Scholar
• Versluis MA, de Jong RA, Plat A, et al. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer. 2015;113:786–793. doi:10.1038/bjc.2015.268
   PubMed Web of Science ®Google Scholar
• Jiang P, Huang Y, Tu Y, et al. Combining clinicopathological parameters and molecular indicators to predict lymph node metastasis in endometrioid type endometrial adenocarcinoma. Front Oncol. 2021;11:682925. doi:10.3389/fonc.2021.682925
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines®) uterine neoplasms version 1.2021; 2020. NCCN Guidelines for Patients®. Available from: www.nccn.org. Accessed May 19, 2022.
   Google Scholar
• Gulseren V, Kocaer M, Ozdemir IA, Cakir I, Sanci M, Gungorduk K. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis? Curr Probl Cancer. 2020;44:100498. doi:10.1016/j.currproblcancer.2019.07.003
   PubMed Web of Science ®Google Scholar
• Ma Y, Lu P, Liang X, Wei S. Models based on dynamic clinicopathological indices for predicting prognosis during the perioperative period for patients with colorectal cancer. J Inflamm Res. 2021;14:1591–1601. doi:10.2147/JIR.S302435
   PubMed Web of Science ®Google Scholar
• Li XY, Yao S, He YT, et al. Score for patients with resectable colorectal cancer. J Inflamm Res. 2021;14:4577–4588. doi:10.2147/JIR.S322260
   PubMed Web of Science ®Google Scholar
• Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23:50. doi:10.1186/s12199-018-0740-1
   PubMed Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, Kuhnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75:689–713. doi:10.1007/s00018-017-2686-7
   PubMed Web of Science ®Google Scholar
• Lu J, Xu BB, Zheng ZF, et al. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized Phase III trial. Gastric Cancer. 2019;22:536–545. doi:10.1007/s10120-018-0892-0
   PubMed Web of Science ®Google Scholar
• Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883. doi:10.1007/s12032-014-0883-x
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Shimodaira S, Nagai K, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother. 2014;63:797–806. doi:10.1007/s00262-014-1554-7
   PubMed Web of Science ®Google Scholar
• Socha MW, Malinowski B, Puk O, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164:103419. doi:10.1016/j.critrevonc.2021.103419
   PubMed Web of Science ®Google Scholar
• Burgess B, Levine B, Taylor RN, Kelly MG. Preoperative circulating lymphocyte and monocyte counts correlate with patient outcomes in type I and type II endometrial cancer. Reprod Sci. 2020;27:194–203. doi:10.1007/s43032-019-00009-4
   PubMed Web of Science ®Google Scholar
• Seebacher V, Grimm C, Reinthaller A, et al. The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol. 2013;171:101–106. doi:10.1016/j.ejogrb.2013.07.044
   PubMed Web of Science ®Google Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–104. doi:10.1016/j.ijgo.2009.02.012
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33–vi38. doi:10.1093/annonc/mdt353
   PubMed Web of Science ®Google Scholar
• Jiang P, Yuan R. Analysis of factors related to lymph node metastasis in early-stage type 1 endometrial cancer: verifying the clinical value of positive threshold of the immunohistochemical parameter Ki67. Cancer Manag Res. 2021;13:6319–6328. doi:10.2147/CMAR.S316211
   PubMed Web of Science ®Google Scholar
• Yang B, Shan B, Xue X, et al. Predicting lymph node metastasis in endometrial cancer using serum CA125 Combined with immunohistochemical markers PR and Ki67, and a comparison with other prediction models. PLoS One. 2016;11:e0155145. doi:10.1371/journal.pone.0155145
   PubMed Web of Science ®Google Scholar
• Jiang P, Jia M, Hu J, et al. Prognostic value of Ki67 in patients with stage 1–2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. Onco Targets Ther. 2020;13:10841–10850. doi:10.2147/OTT.S274420
   PubMed Web of Science ®Google Scholar
• Smith D, Stewart CJR, Clarke EM, et al. ER and PR expression and survival after endometrial cancer. Gynecol Oncol. 2018;148:258–266. doi:10.1016/j.ygyno.2017.11.027
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Ranelletti FO, Gallotta V, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98:383–389. doi:10.1016/j.ygyno.2005.04.024
   PubMed Web of Science ®Google Scholar
• Kobel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. 2019;38:S123–S131. doi:10.1097/PGP.0000000000000488
   PubMed Web of Science ®Google Scholar
• Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T; Cancer Care Ontario Program in Evidence-Based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–529. doi:10.1016/j.ygyno.2006.02.011
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yunokawa M, Sasada S, et al. A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol. 2019;30:e8. doi:10.3802/jgo.2019.30.e8
   PubMed Web of Science ®Google Scholar
• Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding youden index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73–81. doi:10.1097/01.ede.0000147512.81966.ba
   PubMed Web of Science ®Google Scholar
• Austin PC, Harrell FE Jr, Klaveren D. Graphical calibration curves and the integrated calibration index (ICI) for survival models. Stat Med. 2020;39:2714–2742. doi:10.1002/sim.8570
   PubMed Web of Science ®Google Scholar
• Brentnall AR, Cuzick J. Use of the concordance index for predictors of censored survival data. Stat Methods Med Res. 2018;27:2359–2373. doi:10.1177/0962280216680245
   PubMed Web of Science ®Google Scholar
• Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318:1377–1384. doi:10.1001/jama.2017.12126
   PubMed Web of Science ®Google Scholar
• Ouldamer L, Bendifallah S, Body G, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. Br J Cancer. 2016;115:1296–1303. doi:10.1038/bjc.2016.337
   PubMed Web of Science ®Google Scholar
• Mingzhu J, Peng J, Zhen H, Jing H, Ying D, Zhuoying H. The combined ratio of estrogen, progesterone, Ki-67 and P53 to predict the recurrence of endometrial cancer. J Surg Oncol. 2020;122:1808–1814. doi:10.1002/jso.26212
   PubMed Web of Science ®Google Scholar
• Jiang P, Jia M, Hu J, et al. Involving Immunohistochemical markers for predicting the recurrence of stage I-II endometrial cancer. Front Oncol. 2020;10:586081. doi:10.3389/fonc.2020.586081
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12–39. doi:10.1136/ijgc-2020-002230
   PubMed Web of Science ®Google Scholar
• Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019;19:510–521. doi:10.1038/s41568-019-0177-x
   PubMed Web of Science ®Google Scholar
• Leon-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250:312–322. doi:10.1002/path.5373
   PubMed Web of Science ®Google Scholar
• Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:1625–1634. doi:10.1093/jnci/djs374
   PubMedGoogle Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309. doi:10.1016/S1470-2045(18)30079-2
   PubMed Web of Science ®Google Scholar